NASDAQ:PSTV Plus Therapeutics Q2 2026 Earnings Results & Report $0.95 +0.18 (+23.32%) As of 11/13/2026 Plus Therapeutics missed analyst expectations on both earnings and revenue in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$1.31 versus the -$0.88 consensus estimate, while revenue of $411 thousand fell short of the $1.11 million estimate by $702 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeAfter Market ClosesConference Call DateAugust 14, 2026Conference Call7:00 AM ET Plus Therapeutics EPS ResultsActual EPS-$1.31Consensus EPS -$0.88Beat/MissMissed by -$0.43One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersPlus Therapeutics Revenue ResultsActual Revenue$411 thousandExpected Revenue$1.11 millionBeat/MissMissed by -$702.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Plus Therapeutics Q2 2026 Earnings FAQ Did Plus Therapeutics beat earnings estimates for Q2 2026? Plus Therapeutics (NASDAQ:PSTV) reported earnings of -$1.31 per share for Q2 2026, missing the consensus estimate of -$0.88. The report was announced on Thursday, August 13, 2026. What was Plus Therapeutics' revenue for Q2 2026? Plus Therapeutics reported revenue of $411 thousand for Q2 2026, against a consensus estimate of $1.11 million. Plus Therapeutics Earnings HeadlinesPlus Therapeutics (NASDAQ:PSTV) Stock Falls 4.1% - What's Next?November 10, 2026 | americanbankingnews.comCerenome Announces Up to $20 Million Financing Facility with Royalty-Based RepaymentSeptember 10, 2026 | globenewswire.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 16 at 1:00 AM | Base Camp Trading (Ad)Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business LinesAugust 20, 2026 | globenewswire.comCerenome Reports Second Quarter 2026 Financial Results and Business UpdateAugust 14, 2026 | globenewswire.comCerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered LivesAugust 13, 2026 | globenewswire.comSee More Plus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email. Email Address About Plus TherapeuticsPlus Therapeutics (NASDAQ:PSTV) is a clinical-stage biotechnology company developing targeted treatments and diagnostic tools for cancers affecting the central nervous system. Its work includes radiopharmaceutical therapies designed to deliver radiation to tumors while limiting exposure to surrounding healthy tissue. The company’s lead therapeutic program is Rhenium-186 NanoLiposome (RNL), an investigational treatment being studied for cancers including recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics also develops CNSide, a diagnostic platform intended to help detect and monitor cancer cells in cerebrospinal fluid. Previously known as Cytori Therapeutics, the company adopted the Plus Therapeutics name in 2019. It is based in the United States and focuses its development programs on cancers of the brain and central nervous system.View Plus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.